Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 12/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6775942 | 0.90 | CRHR1 (0.42) | CRHR1SMN1; SMN2MAPTRAB9AL3MBTL1 | |
| SCHEMBL6780634 | 0.89 | CRHR1 (0.45) | CRHR1SMN1; SMN2MAPTRAB9AL3MBTL1 | |
| SCHEMBL6775111 | 0.85 | CRHR1 (0.41) | CRHR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6775043 | 0.82 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL6774956 | 0.82 | CRHR1 (0.39) | CRHR1 | |
| SCHEMBL6774526 | 0.82 | CRHR1 (0.53) | CRHR1 | |
| SCHEMBL6773376 | 0.78 | CRHR1 (0.51) | CRHR1SMN1; SMN2MAPTRAB9AL3MBTL1 | |
| SCHEMBL6773897 | 0.76 | CRHR1 (0.58) | CRHR1 | |
| SCHEMBL18173908 | 0.75 | SMN1; SMN2 (0.33) | CRHR1SMN1; SMN2MAPTRAB9AL3MBTL1 | |
| SCHEMBL6780411 | 0.74 | CRHR1 (0.41) | CRHR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030191125-A1 | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-09 | — | — | US | claimed |
| US-20020040026-A1 | Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof | DUPONT PHARMACEUTICALS COMPANY | 2002-04-04 | — | — | US | claimed |
| US-6326368-B1 | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-12-04 | — | — | US | claimed |
| US-6818648-B2 | PSYCHOLOGICAL DISORDERS; ANXIOLYTIC AGENTS; ANTIDEPRESSANTS; EATING DISORDERS; ALCOHOLISM; DRUG ABUSE; ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB PHARMA | 2004-11-16 | — | — | US | disclosed |
| US-20030191125-A1 | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-10-09 | — | — | US | disclosed |
| US-20020040026-A1 | Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof | DUPONT PHARMACEUTICALS COMPANY | 2002-04-04 | — | — | US | disclosed |
| US-6326368-B1 | PSYCHOLOGICAL DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191125-A1 | Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof | PARL, HTR5A, PSEN2 | CRHR1 51/4885SMN1; SMN2 3243/4885MAPT 194/4885 |
| US-20020040026-A1 | Aryloxy-and arylthiosubstituted pyrimidines and triazines and derivatives thereof | PARL, HTR5A, PSEN2 | CRHR1 53/4885SMN1; SMN2 3224/4885MAPT 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.